• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 7
  3. Author

Online ISSN: 2515-8260

Volume9, Issue7

HEREDITARY HAEMORRHAGIC TELANGIECTASIA

    Dr Arpita Krishna ,Dr Gopika Balachandran, Dr Manu S Babu, Dr Mayur Ingale, Dr Yash Jain

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 7333-7337

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Hereditary hemorrhagic telangiectasia or Osler Weber Rendu syndrome is an autosomal dominant vascular disorder that affects multiple systems. It is characterised by skin and mucosal telangiectasias and arteriovenous malformations.
Hereditary  hemorrhagic telangiectasia is a disease more commonly associated with significant morbidity than mortality.It is a rare genetic disorder known for its debilitating symptoms.More than 90% of patients with HHT experience epistaxis,which may cause anaemia if uncontrolled(1,2) and they average upto 18 bleeds per month. Patients also present with arteriovenous malformations in various organs and suffer from many complications including bleeding ,anemia,iron-deficiency, and high output high failure. Families with the same mutation exhibit considerable phenotypic variation
In this case report we present  a 67 year old male with epistaxis on and off since 20 years ,aggravated since last few days around 300-400 ml  along with generalised weakness who came with family  history of similar complaints in 13 members of the family managed with bilateral electrocauterisation of nasal cavities with post op sesame oil application and tab tranexemic acid 250mg OD.Patient is on regular follow up.
Optimal treatment is best delivered a multidisciplinary approach with appropriate diagnosis , screening and local and/or systemic management of lesions.Anti-angiogenic agents such as bevacizumab have emerged as a promising systemic therapy in reducing bleeding complications but are not curative. Other pharmacological agents include iron supplementation, antifibrinolytics and hormone treatment
Keywords:
    Vascular disorder Epistaxis Anaemia iron deficiency
  • PDF (302 K)
  • XML
(2022). HEREDITARY HAEMORRHAGIC TELANGIECTASIA. European Journal of Molecular & Clinical Medicine, 9(7), 7333-7337.
Dr Arpita Krishna ,Dr Gopika Balachandran, Dr Manu S Babu, Dr Mayur Ingale, Dr Yash Jain. "HEREDITARY HAEMORRHAGIC TELANGIECTASIA". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 7333-7337.
(2022). 'HEREDITARY HAEMORRHAGIC TELANGIECTASIA', European Journal of Molecular & Clinical Medicine, 9(7), pp. 7333-7337.
HEREDITARY HAEMORRHAGIC TELANGIECTASIA. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 7333-7337.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 4
  • PDF Download: 18
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus